- $918.18m
- $364.11m
- 41
- 30
- 58
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.71 | ||
| Price to Tang. Book | 1.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.9% | ||
| Return on Equity | -41.33% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 1.07 | 2.5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.
Directors
- Steven Altschuler NEC (67)
- Rohan Palekar CEO (55)
- Ryan Martins CFO (44)
- Ram Waisbourd COO (54)
- Quoc Le-Nguyen CTO (53)
- Hank Mansbach OTH (56)
- Kathleen Laporte DRC (59)
- Derek Di Rocco IND (41)
- Gregory Grunberg IND (48)
- Michael Hayden IND (69)
- Lota Zoth IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 28th, 2019
- Public Since
- November 11th, 2019
- No. of Shareholders
- 5
- No. of Employees
- 70
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 93,501,210
- Address
- 142 Sansome Street, Second Floor, San Francisco, 94104
- Web
- https://www.89bio.com/
- Phone
- +1 4154329270
- Auditors
- KPMG LLP
Upcoming Events for ETNB
Q2 2024 89Bio Inc Earnings Release
Similar to ETNB
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adicet Bio
NASDAQ Global Market
FAQ
What is the 89bio share price?
As of Today at 19:00 UTC, shares in 89bio are trading at $9.82. This share price information is delayed by 15 minutes.
How has the 89bio share price performed this year?
Shares in 89bio last closed at $9.82 and the price had moved by -35.01% over the past 365 days. In terms of relative price strength the 89bio share price has underperformed the S&P500 Index by -47.51% over the past year.
What are the analyst and broker recommendations for 89bio?
The overall consensus recommendation for 89bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the 89bio dividend yield?
89bio does not currently pay a dividend.
Does 89bio pay a dividend?
89bio does not currently pay a dividend.
When does 89bio next pay dividends?
89bio does not currently pay a dividend.
How do I buy 89bio shares?
To buy shares in 89bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of 89bio?
As of the previous close price of $9.82, shares in 89bio had a market capitalisation of $918.18m.
Where are 89bio shares listed?
Here are the trading details for 89bio:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ETNB
What kind of share is 89bio?
Based on an overall assessment of its quality, value and momentum 89bio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a 89bio share price forecast for 2024?
The analyst consensus target price for shares in 89bio is $31.89. That is 224.75% above the last closing price of $9.82.
Analysts covering 89bio currently have a consensus Earnings Per Share (EPS) forecast of -$2.07 for the next financial year.
What is the trend in the 89bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 89bio. Over the past six months, its share price has outperformed the S&P500 Index by +10.01%.
As of the last closing price of $9.82, shares in 89bio were trading -20.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the 89bio PE Ratio?
The 89bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of 89bio?
89bio's management team is headed by:
- Steven Altschuler - NEC
- Rohan Palekar - CEO
- Ryan Martins - CFO
- Ram Waisbourd - COO
- Quoc Le-Nguyen - CTO
- Hank Mansbach - OTH
- Kathleen Laporte - DRC
- Derek Di Rocco - IND
- Gregory Grunberg - IND
- Michael Hayden - IND
- Lota Zoth - IND